Skip to content
Screener

Immunovant, Inc. IMVT Bermuda — Total loss before income taxes

Other geography segments

Switzerland
-$606.29M-53.4%
United States
$100.99M+670%
United Kingdom
-$55K

Similar metrics at other companies

Roivant Sciences logo
ROIVBermuda — Total (loss) income from continuing operations before income taxes
1,559,150,000%+997,064,798pp
Mirion Technologies logo
MIRForeign — Income (loss) before income taxes
$11.98M+26.4%
Q2 Holdings logo
QTWOU.S. — Income (loss) before income taxes
$11.57M+220%
Thor Industries logo
THOTotal North America — INCOME (LOSS) BEFORE INCOME TAXES:
$78.03M-40.2%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — Total income (loss) before income taxes
$115M+94.9%
Roivant Sciences logo
ROIVSwitzerland — Total (loss) income from continuing operations before income taxes
542,775,000%+278,123,885pp

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemYears Ended March 31, 2026Years Ended March 31, 2025Years Ended March 31, 2024
(Loss) income before income taxes
United States$100,991$(17,730)$(16,180)
Switzerland(606,288)(395,119)(242,518)
Bermuda(39)(100)(71)
United Kingdom(55)
Total loss before income taxes$(505,391)$(412,949)$(258,769)
Current taxes
United States – Federal$880$562

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s bermuda — total loss before income taxes?
Immunovant, Inc. (IMVT) reported bermuda — total loss before income taxes of -$9.75K in Q1 2026.
How has Immunovant, Inc.'s bermuda — total loss before income taxes changed year-over-year?
Immunovant, Inc.'s bermuda — total loss before income taxes increased by 61.0% year-over-year, from -$25K to -$9.75K.
What is the long-term trend for Immunovant, Inc.'s bermuda — total loss before income taxes?
Over 4 years (2022 to 2026), Immunovant, Inc.'s bermuda — total loss before income taxes has grown at a -15.6% compound annual growth rate (CAGR), from -$77K to -$39K.
What does bermuda — total loss before income taxes mean?
This metric represents the total pre-tax financial loss attributable to the company's Bermuda-based operations. It reflects the net impact of operating expenses and income generated within this specific geographic segment before accounting for income tax provisions. Monitoring this figure helps investors assess the operational burn rate and financial performance of the entity's offshore or holding company structure.

Ask your AI about Immunovant, Inc.'s bermuda — total loss before income taxes.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude